Calcineurin inhibition in hypertrophy: back from the dead!
Dorn
G W
GW
D000256:Adenoviridae / Q000235:genetics; D000818:Animals; D019703:Calcineurin / Q000235:genetics; D065095:Calcineurin Inhibitors; D002312:Cardiomyopathy, Hypertrophic / Q000188:drug therapy* / Q000201:enzymology / Q000235:genetics / Q000517:prevention & control*; D002352:Carrier Proteins / Q000235:genetics / Q000494:pharmacology; D016572:Cyclosporine / Q000627:therapeutic use; D004268:DNA-Binding Proteins; D004195:Disease Models, Animal; D018628:Gene Dosage; D015870:Gene Expression; D005799:Genes, Dominant; D047908:Intracellular Signaling Peptides and Proteins; D051379:Mice; D008822:Mice, Transgenic; D009124:Muscle Proteins / Q000096:biosynthesis / Q000235:genetics / Q000494:pharmacology; D009154:Mutation; D010455:Peptides / Q000235:genetics / Q000494:pharmacology*; D015398:Signal Transduction / Q000187:drug effects; D016559:Tacrolimus / Q000627:therapeutic use
D065095:Calcineurin Inhibitors; D002352:Carrier Proteins; D004268:DNA-Binding Proteins; D047908:Intracellular Signaling Peptides and Proteins; D009124:Muscle Proteins; D010455:Peptides; C108612:RCAN1 protein, human; D016572:Cyclosporine; D019703:Calcineurin; D016559:Tacrolimus